EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Track record

Tools

  • Compare
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›CING

CING

Cingulate Inc.

Next earnings ≈ Aug 13, 2026 · est. from filing cadence

Last earnings -10.8% on 2026-05-14

Sell
$4.96
▲ 0.00%
$4.96▲ +19.81%
over 1Y
L $3.33EODHDH $11.66
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+4.2%
1M+25.3%
3M-22.4%
YTD+13.2%
1Y+19.8%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
F
Valuation
Fair value
Filings
Watch
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy

High leverage (liabilities/equity 5.0x).

Cingulate Inc. shows limited reported revenue, and -894.8% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue—————
Gross profit—————
Operating income-$20.7M-$17.5M-$22.8M-$15.6M-$19.9M
Net income-$20.7M-$17.7M-$23.5M-$16.6M-$22.4M
Diluted EPS—-$29.35-$311.99-$10.86-$4.44
Net margin—————

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$46.7M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-38.9%
FCF yield-30.2%

Quality & risk

ROIC (est.)-627.8%
Free cash flow-$17.4M
Total debt—
Net cash$11.0M
Piotroski F-Score1/6

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+208.6%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Reg FD disclosure2026-06-16
  2. 8-K Reg FD disclosure2026-06-02
  3. DEF 14A Proxy statement2026-05-29
  4. 8-K Officer / director change2026-05-19
  5. 8-K Earnings results2026-05-14
  6. 10-Q Quarterly report2026-05-14
  7. S-3 Shelf registration (potential raise)2026-04-14
  8. 8-K Officer / director change2026-04-02
  9. 8-K Material agreement2026-03-24

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-162026-06-16open ↗4Period ending 2026-02-132026-06-08open ↗3Period ending 2026-02-132026-06-08open ↗8-KPeriod ending 2026-06-022026-06-02open ↗DEF 14APeriod ending 2026-05-292026-05-29open ↗ARSPeriod ending 2025-12-312026-05-29open ↗DEFA14AFiling2026-05-29open ↗8-KPeriod ending 2026-05-182026-05-19open ↗PRE 14APeriod ending 2026-05-182026-05-18open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗4Period ending 2026-03-312026-05-08open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
GrowthF
ProfitabilityF
Financial healthD
Momentum—
  • ✗Profitable (positive net income)
  • ✗Return on equity above 15%
  • ✗Liabilities below 2× equity
Revenue
—
Net margin
—
ROE
-894.8%
P/E
—

SEC fundamentals · FY 2025

■ revenue · ■ net income, by fiscal year

Net income-$22.4M-35.6%
Operating income-$19.9M-27.4%
Diluted EPS-$4.44+59.1%
Cash & equivalents$11.0M-10.3%
Total assets$15.1M+1.4%
Total liabilities$12.6M+69.6%
Stockholders' equity$2.51M-66.3%
L/E: 5.01x

Frequently asked

Is Cingulate Inc. (CING) a buy?
CING currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. High leverage (liabilities/equity 5.0x).
What is Cingulate Inc.'s quality score?
CING scores 29/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001862150, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:27:16 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-03-09
Silva Raul R.
EVP and CSO
Award4.53K
2026-03-09
Silva Raul R.
EVP and CSO
Tax1.83K
2026-03-09
Schaffer Shane J.
Chief Executive Officer
Award6.86K
2026-03-09
Schaffer Shane J.
Chief Executive Officer
Tax2.96K
2026-03-09
Callahan Jennifer L.
EVP and CFO
Award15.3K
2026-03-09
Callahan Jennifer L.
EVP and CFO
Tax6.43K
2026-03-09
Patel Nilay Dahyabhai
EVP, CLO and CCO
Award5.47K
2026-03-09
Patel Nilay Dahyabhai
EVP, CLO and CCO
Tax2.09K
2026-03-09
Brams Matthew
EVP and Chief Medical Officer
Award4.53K
2026-03-09
Brams Matthew
EVP and Chief Medical Officer
Tax1.02K
2026-02-13
Hargroves Thomas Jeffrey
Director
Buy97.3K @ $5.04$490K
2026-02-06
Werth Peter J.
Director
Buy19.5K @ $5.04$98.1K

Earnings history

beat/miss · move
2026-05-14Miss -108.5% est▼ -10.77%8-K ↗
2026-03-18Miss -44.6% est▼ -31.05%8-K ↗
2025-11-13Miss -63.4% est▼ -12.37%8-K ↗
2025-08-19Miss -21.9% est▼ -9.62%8-K ↗
2025-05-08—▲ +3.81%8-K ↗
2025-03-26—▲ +3.50%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Top Biotech Gainers: ABVX, CING, DRTS, MMED...Bullish
nasdaq.com· 2026-06-04
Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRLBullish
nasdaq.com· 2026-06-03
Biotech Stocks Facing FDA Decision In May 2026Bearish
nasdaq.com· 2026-04-28
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold ForeverBullish
finance.yahoo.com· 2026-04-24
Cingulate price target lowered to $16 from $17 at Roth CapitalBullish
finance.yahoo.com· 2025-11-20
CING: Third Quarter ResultsBullish
finance.yahoo.com· 2025-11-17

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score29 vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity-894.8% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 3d
Bearish
-0.45
vs typical · 3 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.